{
  "title": "Paper_481",
  "abstract": "pmc Sci Rep Sci Rep 1579 scirep Scientific Reports 2045-2322 Nature Publishing Group PMC12484645 PMC12484645.1 12484645 12484645 41028273 10.1038/s41598-025-94336-z 94336 1 Article Probing into 9’-substituted Suzuki-coupled noscapine ionic liquids as potent microtubule targeting anticancer agents with hemoglobin affinity Sewariya Shubham 1 2 6 Mishra Nistha 1 3 Panchal Sagar 1 Kukreti Shrikant 1 Chandra Ramesh acbrdu@hotmail.com rameshchandragroup@gmail.com 1 4 5 6 1 https://ror.org/04gzb2213 grid.8195.5 0000 0001 2109 4999 Department of Chemistry, University of Delhi, 2 https://ror.org/010jbqd54 grid.7943.9 0000 0001 2167 3843 School of Pharmacy and Biomedical Sciences, University of Central Lancashire, 3 https://ror.org/01ztcvt22 grid.440678.9 0000 0001 0674 5044 Department of Biotechnology, Delhi Technological University, 4 https://ror.org/04gzb2213 grid.8195.5 0000 0001 2109 4999 Dr. B. R. Ambedkar Center for Biomedical Research, University of Delhi, 5 https://ror.org/04gzb2213 grid.8195.5 0000 0001 2109 4999 Institute of Nano Medical Sciences, University of Delhi, 6 30 9 2025 2025 15 478255 33734 22 1 2025 13 3 2025 30 09 2025 02 10 2025 02 10 2025 © The Author(s) 2025 2025 https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access http://creativecommons.org/licenses/by-nc-nd/4.0/ On a global scale, lung cancer accounts for 18% of all cancer deaths making it the most lethal cancer. To restrain this, there has been continual research in the domain of microtubule-targeting anticancer agents but issues like toxicity, immunosuppression, effective delivery to tumor site, etc. persist to impede their clinical success. Unlike the other existing drugs in this regime; noscapine (a non-opioid alkaloid) is testified to be an intrinsically safer drug with minimal side effects. In this work, we have synthesized and evaluated novel 9’-substituted suzuki-coupled noscapine ionic liquid(s) as effectual anticancer drug(s) against non-small cell (H1299) lung cancer. We have devised a synthetic route (employed suzuki coupling for subsuming the biaryl pharmacophore and combined it with the idea of active pharmaceutical ingredient-based ionic liquids (API-ILs)) to yield the desired API-ILs followed by their characterization using associated analytical techniques like NMR, HRMS, etc. Following this, we have performed SAR analysis of the API-ILs using molecular docking with the target tubulin protein and preliminary in vitro screening against H1299 (non-small cancer) cells to opt for the most promising analogue i.e., [ p 2 p 2 p 2 b 5 −1 p 2 2 50 p 2 2 p 2 Supplementary Information The online version contains supplementary material available at 10.1038/s41598-025-94336-z. Keywords Noscapine Microtubules Hemoglobin API-IL Lung cancer Biaryl pharmacophore Subject terms Cancer Chemistry pmc-status-qastatus 0 pmc-status-live yes pmc-status-embargo no pmc-status-released yes pmc-prop-open-access yes pmc-prop-olf no pmc-prop-manuscript no pmc-prop-legally-suppressed no pmc-prop-has-pdf yes pmc-prop-has-supplement yes pmc-prop-pdf-only no pmc-prop-suppress-copyright no pmc-prop-is-real-version no pmc-prop-is-scanned-article no pmc-prop-preprint no pmc-prop-in-epmc yes issue-copyright-statement © Springer Nature Limited 2025 Introduction In the 21st century, cancer continues to be one of the most formidable challenges to human health. Based on the recent GLOBOCAN estimates by International Agency for Research on Cancer (IARC), it was solely responsible for 9.7 million deaths in the year 2022 1 2 3 5 6 Nature is a rich source of such microtubule targeting anticancer drugs 7 1 8 11 11 12 14 15 17  Fig. 1 Some microtubule-targeting anticancer drugs from nature. Based on these reports combined with the observation that roughly 50% of the marketed drugs are administrated as salts, we proposed to develop and evaluate novel 9’-substituted suzuki-coupled noscapine based ionic liquids. Ionic liquids are salts, generally composed of organic cations and organic or inorganic counter anions. We aimed at the notion of ionic liquids because of their potential in improving vital properties like solubility, bioavailability, drug delivery etc. of a drug candidate 18 19 20 21 22 23 Herein, we report the synthesis of novel 9’-substituted suzuki-coupled noscapine ionic liquids (Scheme 1 p 2 p 2 p 2 p 2 24 26 27 30 p 2 Chemistry Materials and methods All the purchased reagents and solvents were analytically pure and used without any further purification. The lyophilized powder of human hemoglobin, (S, R)-Noscapine and Pd(PPh 3 4 254 1 13 3 Synthesis of 9’-substituted Suzuki-coupled noscapine ionic liquids Procedure for the synthesis of 9’-substituted Suzuki-coupled noscapinoids In an oven-dried round bottom flask, 9-bromo noscapine 1 2 3 4 1 2 3 2 4 2(a-h)  Scheme 1 Synthetic route to obtain 9’-substituted suzuki-coupled noscapine ionic liquids. Procedure for the synthesis of 9’-substituted Suzuki-coupled noscapine ILs In an oven-dried round bottom flask, the respective compound 2(a-h) 3(a-h) 1 – 3c (S)−5-((S)−4 5-dimethoxy-3-oxo-1 3-dihydroisobenzofuran-1-yl)−4-methoxy-6 6-dimethyl-9-phenyl-5 6 7 8-tetrahydro-[1,3] dioxolo[4 5-g]isoquinolin-6-ium iodide (3a) 1 13 29 30 7 + + (S)−5-((S)−4 5-dimethoxy-3-oxo-1 3-dihydroisobenzofuran-1-yl)−4-methoxy-9-(4-methoxyphenyl)−6 6-dimethyl-5 6 7 8-tetrahydro-[1,3] dioxolo[4 5-g]isoquinolin-6-ium iodide (3b) 1 3 J J J J J 13 3 30 32 8 + + (S)−5-((S)−4 5-dimethoxy-3-oxo-1 3-dihydroisobenzofuran-1-yl)−4-methoxy-6 6-dimethyl-9-(4-nitrophenyl)−5 6 7 8-tetrahydro-[1,3] dioxolo[4 5-g]isoquinolin-6-ium iodide (3c) 1 3 J J J J 13 3 29 29 2 9 + + (S)−5-((S)−4 5-dimethoxy-3-oxo-1 3-dihydroisobenzofuran-1-yl)−4-methoxy-6 6-dimethyl-9-(3-nitrophenyl)−5 6 7 8-tetrahydro-[1,3] dioxolo[4 5-g]isoquinolin-6-ium iodide (3d) 1 3 J J J 13 3 29 29 2 9 + + (S)−9-(3 5-difluorophenyl)−5-((S)−4 5-dimethoxy-3-oxo-1 3-dihydroisobenzofuran-1-yl)−4-methoxy-6 6-dimethyl-5 6 7 8-tetrahydro-[1,3] dioxolo[4 5-g]isoquinolin-6-ium iodide (3e) 1 3 J J J 13 3 29 28 2 7 + + (S)−5-((S)−4 5-dimethoxy-3-oxo-1 3-dihydroisobenzofuran-1-yl)−4-methoxy-6 6-dimethyl-9-(4-(trifluoromethyl)phenyl)−5 6 7 8-tetrahydro-[1,3] dioxolo[4 5-g]isoquinolin-6-ium iodide (3f) 1 3 J J J J J J 13 3 30 29 3 7 + + (S)−5-((S)−4 5-dimethoxy-3-oxo-1 3-dihydroisobenzofuran-1-yl)−4-methoxy-6 6-dimethyl-9-(p-tolyl)−5 6 7 8-tetrahydro-[1,3] dioxolo[4 5-g]isoquinolin-6-ium iodide (3 g) 1 3 J J J J J J 13 3 30 32 7 + + (S)−5-((S)−4 5-dimethoxy-3-oxo-1 3-dihydroisobenzofuran-1-yl)−4-methoxy-6 6-dimethyl-9-(4-vinylphenyl)−5 6 7 8-tetrahydro-[1,3] dioxolo[4 5-g]isoquinolin-6-ium iodide (3 h) 1 3 J J J J 13 3 31 32 7 + + In-silico Molecular Docking and molecular dynamics (MD) simulations Molecular docking was done using AutoDock Vina v1.2.3 31 32 https://www.rcsb.org/ 33 34 35 36 37 2 Table S1 38 46 47 50 Binding free energy calculations MMPBSA/GBSA After successfully getting the trajectories from MD simulations, these trajectories were further used to calculate the binding free energy using Molecular mechanics Poisson-Boltzmann surface area/Generalized-Born surface area (MMPBSA/GBSA) 51 54 In this method the change in binding free energy can be calculated by using Eq. 1 1 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:{\\varDelta\\:G}_{bind}=\\:<{G}_{COM}>-\\:<{G}_{REC}>-\\:<{G}_{LIG}>$$\\end{document} Each term on the right-hand side can be calculated using the following Eq. 2 2 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:<{G}_{x}>\\:=\\:<{E}_{MM}>\\:+\\:\\:<{G}_{sol}>\\:-\\:<TS>$$\\end{document} which can also be written as 3 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:{\\varDelta\\:G}_{bind}=\\:\\varDelta\\:H-T\\varDelta\\:S$$\\end{document} where ΔG is change in Gibb’s free energy, ΔH represents enthalpy of binding and ΔS corresponds to the conformational entropy after ligand binds with the receptor. Spectroscopic studies A 1X phosphate buffer (PBS) with a pH of 7.4 was used for all biophysical experiments. A 2.5 µM Hb stock solution was prepared and kept at 4 °C until use. This solution was utilized for UV-Visible and fluorescence spectroscopy, whereas a more diluted sample with a concentration of 1 µM was used for circular dichroism spectroscopy. UV-Visible spectroscopy To probe into [ p 2 −6 p 2 Fluorescence spectroscopy We recorded the fluorescence spectra on Hitachi F-7000 Fluorescence Spectrophotometer. Firstly, we recorded the spectrum of hemoglobin and subsequently titrated with increasing concentrations of [ p 2 For appropriate evaluation of the spectral data, we accounted for the inner filter effect (reduction of fluorescence intensity due to ligand’s absorbance at the excitation or emission wavelength) and corrected it by applying the following Eq. (4): 4 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$${F}_{corrected} ={F}_{observed}.e^{(Aex+Aem)/2}$$\\end{document} Herein, F observed F corrected A ex A em Circular dichroism spectroscopy We recorded the far-UV CD spectra on a Jasco J-815 spectrophotometer. Initially, we recorded the hemoglobin spectrum and then titrated with stepwise increasing concentrations of [ p 2 Biology Cell culture and reagents All the chemicals were purchased from Sigma Aldrich, SRL and [ p 2 1 2 2 p 2 3 In vitro The colorimetric 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium bromide (MTT) assay was used for assessing the inhibition of cell proliferation in H1299 and A549 cell line. The cancer cells were harvested using trypsin & then seeded into 96-well microplates with ~ 10 × 10 3 2 2 p 2 p 2 −1 2 50 2 p 2 Results and discussion General Suzuki coupling is the palladium catalyzed cross-coupling reaction between aryl halides and aryl boronic acids using an aqueous base. It is one of the top reactions exploited for the synthesis of drug leads in medicinal chemistry via introduction of the biaryl pharmacophore (Csp 2 2 55 1 56 1 1 3 4 2 3 57 As documented in the literature, Structure activity relationship (SAR) analysis 58 2 2 2 para 2 p 2 −1  Fig. 2 ( a b In the onward sections, we have discussed the molecular docking of all API-ILs with tubulin followed by molecular simulations and binding free energy calculations for [ p 2 p 2 2 p 2 In-silico evaluation: interaction with tubulin Molecular docking and MD simulations The visualization of possible interactions between protein and drug i.e., [ p 2 1  Table 1 Molecular Docking scores of synthesized ionic liquids with tubulin. S.No. Code Structure of ionic liquid Docking score (kcalmol −1 1. 3a  −8.9 2. 3b  −9.6 3. 3c   −10.0 4. 3d  −9.5 5. 3e  −8.1 6. 3f  −9.4 7. 3g  −9.5 8. 3h  −9.5 9. Noscapine  −8.7 From Table 1 −1 p 2 p 2 3 2 3  Fig. 3 Three dimensional docked poses of ( a p 2 b  Fig. 4 MD simulation results of [ p 2 a b c d Using the final trajectories, RMSD (root mean square deviations) and RMSF (root mean square fluctuations) were calculated to examine the conformational flexibility in the protein structure at normal temperature and pressure conditions. As we can see in Fig. 4 p 2 4 4 Solvent Accessible Surface Area (SASA) analysis aided in understanding the compactness of the protein using area covered by either solvent or ligand/drug 59 4 p 2 In addition, Radius of gyration (Rg) can be defined as the mass-weighted root mean square deviations of the collection of atoms from their ground state of mass. A study of the Rg provides an understanding of the overall deviation in protein dimension namely deviation in secondary structure of the protein from its ground state. As we can see in Fig. 4 p 2 Binding free energy MMPBSA/GBSA calculations The MMPBSA/GBSA is another useful method to calculate the binding free energies of the ligands under assessment. The binding free energy analysis has been executed with the MM-PBSA/GBSA approach for the trajectories obtained from MD simulations during a period of 10 ns. The detailed Poisson Boltzmann analysis is listed in Table 2 3  Table 2 Molecular mechanics Poisson Boltzmann surface area (MM-PBSA) analysis. Energy component Complex* Receptor* Ligand* \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:{\\varDelta\\:\\varvec{G}}_{bind}$$\\end{document} BOND 1334.75 1317.09 17.66 0 ANGLE 3527.44 3481.37 46.07 0 DIHED 4410.89 4373.76 37.13 0 VDWAALS −3358.68 −3321.08 −9.07 −28.53 EEL −28433.14 −28232.95 8.14 −208.33 1–4 VDW 1585.38 1572.40 12.98 0 1–4 EEL 18213.88 18158.69 55.19 0 EPB −7350.24 −7506.09 −64.83 220.68 ENPOLAR 105.72 104.90 3.81 −2.99 EDISPER 0.00 0.00 0 0 GGAS −2719.50 −2650.73 168.1 −236.87 GSOLV −7244.52 −7401.19 −61.03 217.69 Total −9964.02 −10051.92 107.07 −19.18 *All units are reported in kcalmol −1  Table 3 Molecular mechanics generalized born surface area (MM-GBSA) analysis. Energy Component Complex* Receptor* Ligand* \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:{\\varDelta\\:\\varvec{G}}_{bind}$$\\end{document} BOND 1334.75 1317.09 17.66 0 ANGLE 3527.44 3481.37 46.07 0 DIHED 4410.89 4373.76 37.13 0 VDWAALS −3358.68 −3321.08 −9.07 −28.53 EEL −28433.1 −28,233 8.14 −208.33 1–4 VDW 1585.38 1572.4 12.98 0 1–4 EEL 18213.88 18158.69 55.19 0 EGB −7322.69 −7470.24 −68.19 215.73 ESURF 165.28 164.54 4.37 −3.63 GGAS −2719.5 −2650.73 168.1 −236.87 GSOLV −7157.42 −7305.7 −63.81 212.1 Total −9876.91 −9956.43 104.29 −24.77 *All units are reported in kcalmol −1 From MM-PBSA and MM-GBSA analysis, we can see that the net change is binding free energy for [ p 2 −1 −1 Spectroscopic evaluation: biophysical interaction with Hb Absorption spectral studies Herein, UV-Visible Absorption spectroscopy is a conventional choice for understanding the drug-protein interactions because both α and β bands along with the soret band in hemoglobin are susceptible to even the slightest of structural modifications 60 61 max max max 27 62 p 2 5 ) 63 5 2  Fig. 5 UV-Visible absorption spectra of ( a p 2 b p 2 Fluorescence spectral studies As a result of the intrinsic fluorescence of proteins, fluorescence spectroscopy has become a vital tool to assess the binding between proteins and drugs. It can be used to comprehend the binding mechanism and then later calculate the binding and thermodynamic parameters. Human Hemoglobin contains a total of six tryptophan residues (two α-Trp14, two β-Trp15 and two β-Trp37) 64 1 2 65 67 p 2 6 6 p 2  Fig. 6 Emission spectra of Hb against different concentrations of [p 2 a b c Consequent upon spotting quenching in all emission spectra (298 K, 303 K and 308 K), we used this data to further scrutinize and ensure the quenching mechanism. ( 7 ) 68 F 0 /F [Q] ( 5 ( 6 ( 7 68 70 5 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\frac{{\\text{F}}_{\\text{o}}}{F}\\text{=}{\\text{1+K}}_{sv}\\left[Q\\right]=\\:{\\text{K}}_{q}{\\tau}_{o}\\left[Q\\right]$$\\end{document} 6 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\frac{{\\text{F}}_{\\text{o}}}{F}\\text{=}{\\text{1+K}}_{s}\\left[Q\\right]$$\\end{document} 7 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\frac{{\\text{F}}_{\\text{o}}}{F}\\text{=}{\\text{(1+K}}_{D}\\left[Q\\right]\\left){\\text{(1+K}}_{S}\\left[Q\\right]\\right)$$\\end{document} Herein, F F o p 2 [Q] K sv K q K S K D \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$${\\tau}_{o}$$\\end{document} −8 64 71  Fig. 7 Stern Volmer plot of Hb against different concentrations of ( a p 2 b p 2 From Fig. 7 F o F [Q] ( 7 ) K sv K q 4 K sv K q K q 12 −1 −1 10 −1 −1 p 2 69 72 74  Table 4 Stern Volmer and bimolecular quenching constants for [ p 2 Temperature (K) K sv −1 4 K q −1 −1 12 298 1.6509 1.6509 303 1.7327 1.7327 308 2.4507 2.4507 Subsequently, we employed the modified Stern-Volmer ( 8 69 p 2 8 8 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:log\\left(\\frac{{\\text{F}}_{\\text{o}}-F}{F}\\right)={\\text{logK}}_{b}\\:\\text{+nlog}\\left[Q\\right]$$\\end{document} Herein, K b n b 8 5 5 n p 2 5 −1 8 9 10 9 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:{\\text{lnK}}_{b}=-\\frac{\\varDelta\\:H}{RT}+\\frac{\\varDelta\\:S}{R}$$\\end{document} 10 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\varDelta\\:G=\\varDelta\\:H-T\\varDelta\\:S$$\\end{document} In these equations, R denotes the universal gas constant (8.314 Jmol −1 −1 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\varDelta\\:G$$\\end{document} \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\varDelta\\:H\\:$$\\end{document} \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\varDelta\\:S$$\\end{document}  Fig. 8 ( a b p 2  Table 5 Thermodynamic parameters for [ p 2 Temperature (Kelvin) K b −1  n \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\varDelta\\:\\mathbf{G}\\:$$\\end{document} −1 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\varDelta\\:\\mathbf{H}\\:$$\\end{document} −1 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\varDelta\\:\\mathbf{S}\\:$$\\end{document} −1 −1 298 1.38 × 10 5 1.20 −28.949 −155.043 −423.132 303 30,903 1.00 308 18,197 1.02 From Table 5 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\varDelta\\:G$$\\end{document} −1 \\documentclass[12pt]{minimal}\n\t\t\t\t\\usepackage{amsmath}\n\t\t\t\t\\usepackage{wasysym} \n\t\t\t\t\\usepackage{amsfonts} \n\t\t\t\t\\usepackage{amssymb} \n\t\t\t\t\\usepackage{amsbsy}\n\t\t\t\t\\usepackage{mathrsfs}\n\t\t\t\t\\usepackage{upgreek}\n\t\t\t\t\\setlength{\\oddsidemargin}{-69pt}\n\t\t\t\t\\begin{document}$$\\:\\varDelta{H}\\:and\\:\\varDelta{S}$$\\end{document} p 2 75 Circular dichroism spectral studies CD spectroscopy is a useful study to probe into [ p 2 76 9 77 p 2 9 78 6 p 2 p 2  Fig. 9 Far-UV CD spectrum of Hb in presence and absence of [p-NO 2  Table 6 Assessment of secondary structure of hb during [ p 2 Secondary structures Details of secondary structures Percentage content of secondary structure Hb 1:1 1:3 1:5 Helix 23.8 21.3 5.5 3.4 Antiparallel Anti 1 (Left-twisted) 4.4 1.9 0.0 8.0 Anti 2 (Relaxed) 0.0 0.0 7.5 8.9 Anti 3 (Right twisted) 10.7 9.8 12.7 16.0 Parallel 9.4 11.5 14.7 11.6 Turns 16.0 15.2 12.6 10.7 Others 35.6 40.3 47.0 41.4 Biological evaluation against cancer (H1299 and A549) cell line: MTT assay To analyze the efficacy of the compelling API-IL i.e. [ p 2 p 2 2 10 p 2 2 50 50 50 2 p 2 11 p 2 50 50 2 50 Next, we used the A549 cell line (another non-small cancer cell line) to further investigate the efficacy of the API-IL [ p 2 12 50 p 2 50 50  Fig. 10 Cytotoxicity profile of [ p 2 2 a b  Fig. 11 Microscopic images of H1299 cells exposed to different concentrations of [ p 2 a b Lastly, we compared the effectiveness of [ p 2 12 50 50 p 2  Fig. 12 Cytotoxicity profile of ( a p 2 b p 2 Conclusion Lung cancer is responsible for high death rates and huge socio-economic losses across international boundaries. Consequentially, the quest for anticancer agents continues with an emphasis on development of compounds that can disrupt critical cellular processes essential for tumor proliferation. Among widespread compounds under investigation, noscapine derivatives have acquired significant attention due to their inherent ability to bind to tubulin (a key protein involved in mitotic spindle formation). In this context, we have synthesized 9’-substituted suzuki -coupled noscapine ionic liquids representing a promising strategy to enhance the potency and efficacy of noscapine analogues against non-small cell lung cancer. We made use of the acclaimed suzuki-coupling to introduce the biaryl pharmacophore and later methylated the nitrogen to form the API-ILs which were thoroughly characterized. Using preliminary in silico and in vitro investigations, we then opted for the most potent API-IL which turned out to be [ p 2 p 2 p 2 b 5 −1 50 p 2 Electronic supplementary material Below is the link to the electronic supplementary material.  Supplementary Material 1 Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Acknowledgements R.C. is grateful to University of Delhi for providing lab facility. S.S. (Grant no. – 09/045 (1739)/2019-EMR-I) would like to thank Council of Scientific and Industrial Research (CSIR) for providing Senior Research Fellowship. All the authors are thankful to USIC, University of Delhi for providing instrumentation facilities. Author contributions Shubham Sewariya – Conceptualization, Methodology, Investigation, Data Curation, Writing-Original Draft, Visualization.Nistha Mishra – Methodology, Investigation, Data CurationSagar Panchal – Methodology, Investigation, Data CurationShrikant Kukreti – Validation, Resources, Supervision.Ramesh Chandra – Conceptualization, Validation, Resources, Writing-Review & Editing, Supervision, Funding Acquisition. Data availability The data has been provided as supplementary information. Declarations Conflict of interest The authors have no conflict of interest to declare. References 1. Bray F Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J. Clin. 2024 74 229 263 10.3322/caac.21834 38572751 Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74 38572751 10.3322/caac.21834 2. Olaussen KA Postel-Vinay S Predictors of chemotherapy efficacy in non-small-cell lung cancer: A challenging landscape Ann. Oncol. 2016 27 2004 2016 10.1093/annonc/mdw321 27502726 Olaussen, K. A. & Postel-Vinay, S. Predictors of chemotherapy efficacy in non-small-cell lung cancer: A challenging landscape. Ann. Oncol. 27 27502726 10.1093/annonc/mdw321 3. Fu XY Three rounds of stability-guided optimization and systematical evaluation of oncolytic peptide LTX-315 J. Med. Chem. 2024 67 3885 3908 10.1021/acs.jmedchem.3c02232 38278140 Fu, X. Y. et al. Three rounds of stability-guided optimization and systematical evaluation of oncolytic peptide LTX-315. J. Med. Chem. 67 38278140 10.1021/acs.jmedchem.3c02232 4. Yin H The hybrid oncolytic peptide NTP-385 potently inhibits adherent cancer cells by targeting the nucleus Acta Pharmacol. Sin 2023 44 201 210 10.1038/s41401-022-00939-x 35794372 PMC9813345 Yin, H. et al. The hybrid oncolytic peptide NTP-385 potently inhibits adherent cancer cells by targeting the nucleus. Acta Pharmacol. Sin 44 35794372 10.1038/s41401-022-00939-x PMC9813345 5. Yin H Design, synthesis and anticancer evaluation of novel oncolytic peptide-chlorambucil conjugates Bioorg. Chem. 2023 138 106674 10.1016/j.bioorg.2023.106674 37331169 Yin, H. et al. Design, synthesis and anticancer evaluation of novel oncolytic peptide-chlorambucil conjugates. Bioorg. Chem. 138 37331169 10.1016/j.bioorg.2023.106674 6. Dumontet C Jordan MA Microtubule-binding agents: A dynamic field of cancer therapeutics Nat. Rev. Drug Discov 2010 9 790 803 10.1038/nrd3253 20885410 PMC3194401 Dumontet, C. & Jordan, M. A. Microtubule-binding agents: A dynamic field of cancer therapeutics. Nat. Rev. Drug Discov 9 20885410 10.1038/nrd3253 PMC3194401 7. Newman DJ Cragg GM Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019 J. Nat. Prod. 2020 83 770 803 10.1021/acs.jnatprod.9b01285 32162523 Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. J. Nat. Prod. 83 32162523 10.1021/acs.jnatprod.9b01285 8. Rida PCG Livecche D Ogden A Zhou J Aneja R The Noscapine chronicle: A Pharmaco-Historic biography of the opiate alkaloid family and its clinical applications Med. Res. Rev. 2015 35 1072 1096 10.1002/med.21357 26179481 PMC4778555 Rida, P. C. G., Livecche, D., Ogden, A., Zhou, J. & Aneja, R. The Noscapine chronicle: A Pharmaco-Historic biography of the opiate alkaloid family and its clinical applications. Med. Res. Rev. 35 26179481 10.1002/med.21357 PMC4778555 9. Ye, K. et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells, (1998). www.pnas.org 10.1073/pnas.95.4.1601 PMC19111 9465062 10. Zhou J Panda D Landen JW Wilson L Joshi HC Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint J. Biol. Chem. 2002 277 17200 17208 10.1074/jbc.M110369200 11864974 Zhou, J., Panda, D., Landen, J. W., Wilson, L. & Joshi, H. C. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J. Biol. Chem. 277 11864974 10.1074/jbc.M110369200 11. Ke Y Noscapine inhibits tumor growth with little toxicity to normal tissues or Inhibition of immune responses Cancer Immunol. Immunother. 2000 49 217 225 10.1007/s002620000109 10941904 PMC11036989 Ke, Y. et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or Inhibition of immune responses. Cancer Immunol. Immunother. 49 10941904 10.1007/s002620000109 PMC11036989 12. Jain N Synthesis and antitumor evaluation of Nitrovinyl biphenyls: anticancer agents based on allocolchicines ChemMedChem 2011 6 859 868 10.1002/cmdc.201100019 21472861 Jain, N. et al. Synthesis and antitumor evaluation of Nitrovinyl biphenyls: anticancer agents based on allocolchicines. ChemMedChem 6 21472861 10.1002/cmdc.201100019 13. Marzaro G Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors J. Med. Chem. 2014 57 4598 4605 10.1021/jm500034j 24801610 PMC4086859 Marzaro, G. et al. Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors. J. Med. Chem. 57 24801610 10.1021/jm500034j PMC4086859 14. Yu FL Discovery of novel antitumor dibenzocyclooctatetraene derivatives and related biphenyls as potent inhibitors of NF-κB signaling pathway Bioorg. Med. Chem. 2014 22 325 333 10.1016/j.bmc.2013.11.018 24315191 PMC3899348 Yu, F. L. et al. Discovery of novel antitumor dibenzocyclooctatetraene derivatives and related biphenyls as potent inhibitors of NF-κB signaling pathway. Bioorg. Med. Chem. 22 24315191 10.1016/j.bmc.2013.11.018 PMC3899348 15. Porcù E Novel 9′-substituted-noscapines: synthesis with Suzuki cross-coupling, structure Elucidation and biological evaluation Eur. J. Med. Chem. 2014 84 476 490 10.1016/j.ejmech.2014.07.050 25050880 PMC4143145 Porcù, E. et al. Novel 9′-substituted-noscapines: synthesis with Suzuki cross-coupling, structure Elucidation and biological evaluation. Eur. J. Med. Chem. 84 25050880 10.1016/j.ejmech.2014.07.050 PMC4143145 16. Dash SG Suri C Nagireddy PKR Kantevari S Naik PK Rational design of 9-vinyl-phenyl Noscapine as potent tubulin binding anticancer agent and evaluation of the effects of its combination on docetaxel J. Biomol. Struct. Dyn. 2021 39 5276 5289 10.1080/07391102.2020.1785945 32608323 Dash, S. G., Suri, C., Nagireddy, P. K. R., Kantevari, S. & Naik, P. K. Rational design of 9-vinyl-phenyl Noscapine as potent tubulin binding anticancer agent and evaluation of the effects of its combination on docetaxel. J. Biomol. Struct. Dyn. 39 32608323 10.1080/07391102.2020.1785945 17. Santoshi S Rational design of biaryl pharmacophore inserted Noscapine derivatives as potent tubulin binding anticancer agents J. Comput. Aided Mol. Des. 2015 29 249 270 10.1007/s10822-014-9820-5 25481458 Santoshi, S. et al. Rational design of biaryl pharmacophore inserted Noscapine derivatives as potent tubulin binding anticancer agents. J. Comput. Aided Mol. Des. 29 25481458 10.1007/s10822-014-9820-5 18. Zhuang, W. et al. Ionic liquids in pharmaceutical industry: A systematic review on applications and future perspectives. J. Mol. Liq 349 19. Pedro SN Freire CSR Silvestre AJD Freire MG Ionic liquids in drug delivery Encyclopedia 2021 1 324 339 10.3390/encyclopedia1020027 Pedro, S. N., Freire, C. S. R., Silvestre, A. J. D. & Freire, M. G. Ionic liquids in drug delivery. Encyclopedia 1 20. Hough WL The third evolution of ionic liquids: active pharmaceutical ingredients New J. Chem. 2007 31 1429 1436 10.1039/b706677p Hough, W. L. et al. The third evolution of ionic liquids: active pharmaceutical ingredients. New J. Chem. 31 21. Egorova KS Gordeev EG Ananikov VP Biological activity of ionic liquids and their application in pharmaceutics and medicine Chem. Rev. 2017 117 7132 7189 10.1021/acs.chemrev.6b00562 28125212 Egorova, K. S., Gordeev, E. G. & Ananikov, V. P. Biological activity of ionic liquids and their application in pharmaceutics and medicine. Chem. Rev. 117 28125212 10.1021/acs.chemrev.6b00562 22. Dias, A. R., Costa-Rodrigues, J., Fernandes, M. H., Ferraz, R. & Prudêncio, C. The Anticancer Potential of Ionic Liquids, ChemMedChem 12 11–18. (2017). 10.1002/cmdc.201600480 10.1002/cmdc.201600480 27911045 23. Sewariya, S. et al. Comparative assessment of 9-bromo Noscapine ionic liquid and Noscapine: synthesis, in-vitro studies plus computational & biophysical evaluation with human hemoglobin. Int. J. Biol. Macromol. 247 10.1016/j.ijbiomac.2023.125791 37442512 24. Vijayan, V., Uthaman, S. & Park, I. K. Cell membrane-camouflaged nanoparticles: A promising biomimetic strategy for cancer theragnostics. Polym. (Basel) 10.3390/polym10090983 PMC6404000 30960908 25. Tian, H. et al. Cancer cell Membrane-Biomimetic oxygen nanocarrier for breaking Hypoxia-Induced chemoresistance. Adv. Funct. Mater. 27 26. Biagiotti, S., Pirla, E. & Magnani, M. Drug transport by red blood cells. Front. Physiol. 14 10.3389/fphys.2023.1308632 PMC10750411 38148901 27. Sehrawat, H. et al. Unraveling the interaction of an opium poppy alkaloid Noscapine ionic liquid with human hemoglobin: biophysical and computational studies. J. Mol. Liq 338 28. Sehrawat, H. et al. Mechanistic interaction of triflate based Noscapine ionic liquid with BSA: spectroscopic and chemoinformatics approaches. J. Mol. Liq 315 29. Sehrawat H Kumar N Panchal S Kumar L Chandra R Imperative persistent interaction analysis of anticancer noscapine-ionic liquid with calf thymus DNA Int. J. Biol. Macromol. 2022 220 415 425 10.1016/j.ijbiomac.2022.08.106 35985396 Sehrawat, H., Kumar, N., Panchal, S., Kumar, L. & Chandra, R. Imperative persistent interaction analysis of anticancer noscapine-ionic liquid with calf thymus DNA. Int. J. Biol. Macromol. 220 35985396 10.1016/j.ijbiomac.2022.08.106 30. Panchal, S., Sehrawat, H., Sharma, N. & Chandra, R. Biochemical interaction of human hemoglobin with ionic liquids of noscapinoids: spectroscopic and computational approach. Int. J. Biol. Macromol. 239 10.1016/j.ijbiomac.2023.124227 37003390 31. Trott O Olson AJ AutoDock Vina: improving the speed and accuracy of Docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 2010 31 455 461 10.1002/jcc.21334 19499576 PMC3041641 Trott, O. & Olson, A. J. AutoDock Vina: improving the speed and accuracy of Docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31 19499576 10.1002/jcc.21334 PMC3041641 32. Allinger NL Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms J. Am. Chem. Soc. 1977 99 25 8127 8134 10.1021/ja00467a001 AllingerN. L. Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J. Am. Chem. Soc. 99 33. Nogales, E., Wolf, S. G. & Downing, K. H. Structure of the tubulin dimer by electron crystallography, (1998). 10.1038/34465 9428769 34. Berman HM Protein Data Bank Nucleic Acids Res. 2000 28 235 242 10.1093/nar/28.1.235 10592235 PMC102472 Berman, H. M. et al. Protein Data Bank. Nucleic Acids Res. 28 10592235 10.1093/nar/28.1.235 PMC102472 35. Biovia DS Dassault systèmes BIOVIA, discovery studio V.sualizer, V. 17.2, San Diego: Dassault systèmes, 2016 J. Chem. Phys. 2000 10 21 9991 Biovia, D. S. et al. Dassault systèmes BIOVIA, discovery studio V.sualizer, V. 17.2, San Diego: Dassault systèmes, 2016. J. Chem. Phys. 10 36. DeLano, W. L. The PyMOL Molecular Graphics System, DeLano Scientific (2002). 37. Morris GM Software news and updates AutoDock4 and AutoDockTools4: automated Docking with selective receptor flexibility J. Comput. Chem. 2009 30 2785 2791 10.1002/jcc.21256 19399780 PMC2760638 Morris, G. M. et al. Software news and updates AutoDock4 and AutoDockTools4: automated Docking with selective receptor flexibility. J. Comput. Chem. 30 19399780 10.1002/jcc.21256 PMC2760638 38. Bekker, H. J. C. et al. Gromacs-a parallel computer for molecular-dynamics simulations, In 4th international conference on computational physics (PC 92) 39. Abraham MJ Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers SoftwareX 2015 1-2 19 25 10.1016/j.softx.2015.06.001 Abraham, M. J. et al. Gromacs: high performance molecular simulations through multi-level parallelism from laptops to supercomputers. SoftwareX 1-2 40. Páll, S., Abraham, M. J., Kutzner, C., Hess, B. & Lindahl, E. Tackling Exascale Software Challenges in Molecular Dynamics Simulations with GROMACS, (2015). http://link.springer.com/chapter/10 41. Pronk S GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit Bioinformatics 2013 29 845 854 10.1093/bioinformatics/btt055 23407358 PMC3605599 Pronk, S. et al. GROMACS 4.5: A high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29 23407358 10.1093/bioinformatics/btt055 PMC3605599 42. Hess B Kutzner C Van Der Spoel D Lindahl E GRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation J. Chem. Theory Comput. 2008 4 435 447 10.1021/ct700301q 26620784 Hess, B., Kutzner, C., Van Der Spoel, D. & Lindahl, E. GRGMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J. Chem. Theory Comput. 4 26620784 10.1021/ct700301q 43. Van Der Spoel D GROMACS: fast, flexible, and free J. Comput. Chem. 2005 26 1701 1718 10.1002/jcc.20291 16211538 Van Der Spoel, D. et al. GROMACS: fast, flexible, and free. J. Comput. Chem. 26 16211538 10.1002/jcc.20291 44. Lindahl E Hess B van der Spoel D GROMACS 3.0: A package for molecular simulation and trajectory analysis J. Mol. Model. 2001 7 306 317 10.1007/S008940100045 Lindahl, E., Hess, B. & van der Spoel, D. GROMACS 3.0: A package for molecular simulation and trajectory analysis. J. Mol. Model. 7 45. Berendsen, H. J. C., Van Der Spoel, D. & Van Drunen, R. GROMACS: A message-passing parallel molecular dynamics implementation PROGRAM SUMMARY Title of program: GROMACS version 1.0, (1995). 46. Lindorff-Larsen K Improved side-chain torsion potentials for the amber ff99SB protein force field Proteins: Struct. Function Bioinf. 2010 78 1950 1958 10.1002/prot.22711 PMC2970904 20408171 Lindorff-Larsen, K. et al. Improved side-chain torsion potentials for the amber ff99SB protein force field. Proteins: Struct. Function Bioinf. 78 10.1002/prot.22711 PMC2970904 20408171 47. Wang, J., Wang, W., Kollman, P. A. & Case, D. A. Antechamber, An Accessory Software Package For Molecular Mechanical Calculations Correspondence to, n.d. 48. Silva, D. & Vranken, B. F. ACPYPE-AnteChamber PYthon Parser interfacE, (2012). http://www.biomedcentral.com/1756-0500/5/367 10.1186/1756-0500-5-367 PMC3461484 22824207 49. Wang J Wolf RM Caldwell JW Kollman PA Case DA Development and testing of a general amber force field J. Comput. Chem. 2004 25 1157 1174 10.1002/jcc.20035 15116359 Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25 15116359 10.1002/jcc.20035 50. Wang J Wang W Kollman PA Case DA Automatic atom type and bond type perception in molecular mechanical calculations J. Mol. Graph Model. 2006 25 247 260 10.1016/j.jmgm.2005.12.005 16458552 Wang, J., Wang, W., Kollman, P. A. & Case, D. A. Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graph Model. 25 16458552 10.1016/j.jmgm.2005.12.005 51. Valdés-Tresanco MS Valdés-Tresanco ME Valiente PA Moreno E Gmx_MMPBSA: A new tool to perform End-State free energy calculations with GROMACS J. Chem. Theory Comput. 2021 17 6281 6291 10.1021/acs.jctc.1c00645 34586825 Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A. & Moreno, E. Gmx_MMPBSA: A new tool to perform End-State free energy calculations with GROMACS. J. Chem. Theory Comput. 17 34586825 10.1021/acs.jctc.1c00645 52. Wang E End-Point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design Chem. Rev. 2019 119 9478 9508 10.1021/acs.chemrev.9b00055 31244000 Wang, E. et al. End-Point binding free energy calculation with MM/PBSA and MM/GBSA: strategies and applications in drug design. Chem. Rev. 119 31244000 10.1021/acs.chemrev.9b00055 53. Genheden S Ryde U The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities Expert Opin. Drug Discov 2015 10 449 461 10.1517/17460441.2015.1032936 25835573 PMC4487606 Genheden, S. & Ryde, U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin. Drug Discov 10 25835573 10.1517/17460441.2015.1032936 PMC4487606 54. Wang, C., Greene, D., Xiao, L., Qi, R. & Luo, R. Recent developments and applications of the MMPBSA method. Front. Mol. Biosci. 4 10.3389/fmolb.2017.00087 PMC5768160 29367919 55. Bai, L. & Wang, J. X. Environmentally Friendly Suzuki Aryl-Aryl Cross-Coupling Reaction, (2005). 56. Zhou, J. et al. Brominated derivatives of Noscapine are potent Microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol. Pharmacol. 3 http://molpharm.aspetjournals.org 10.1124/mol.63.4.799 12644580 57. Ahad F Ganie SA Iodine, iodine metabolism and iodine deficiency disorders revisited Indian J. Endocrinol. Metabol. 2010 14 1 13 17 PMC3063534 21448409 Ahad, F. & Ganie, S. A. Iodine, iodine metabolism and iodine deficiency disorders revisited. Indian J. Endocrinol. Metabol. 14 PMC3063534 21448409 58. Liew, S. K., Malagobadan, S., Arshad, N. M. & Nagoor, N. H. A review of the structure—activity relationship of natural and synthetic antimetastatic compounds. Biomolecules 10 10.3390/biom10010138 PMC7022821 31947704 59. by A. Bondi, THE JOURNAL OF PHYSICAL CHEMISTRY Registered in U. S. Patent Office© der Waals Volumes and Radii, UTC, 2024. https://pubs.acs.org/sharingguidelines. 60. Dimer, H. H., Nichols, W. L., Zimm, B. H., Ten, L. F. & Eyck Conformation-invariant Structures of the α1 β1 Human Hemoglobin Dimer, (1997). 10.1006/jmbi.1997.1087 9245590 61. Zagrean-Tuza, C., Igescu, I., Lupan, A. & Silaghi-Dumitrescu, R. A study of the molecular interactions of hemoglobin with diverse classes of therapeutic agents. Inorganica Chim. Acta 567 62. Liu W Ding F Sun Y Characterization of phenosafranine-hemoglobin interactions in aqueous solution J. Solut. Chem. 2011 40 231 246 10.1007/s10953-010-9647-1 Liu, W., Ding, F. & Sun, Y. Characterization of phenosafranine-hemoglobin interactions in aqueous solution. J. Solut. Chem. 40 63. Chugh H Ex vivo binding studies of the anti-cancer drug Noscapine with human hemoglobin: a spectroscopic and molecular Docking study New J. Chem. 2021 45 1525 1534 10.1039/d0nj03334k Chugh, H. et al. Ex vivo binding studies of the anti-cancer drug Noscapine with human hemoglobin: a spectroscopic and molecular Docking study. New J. Chem. 45 64. Wang YQ Zhang HM Tang BP The interaction of C.I. Acid red 27 with human hemoglobin in solution J. Photochem. Photobiol B 2010 100 76 83 10.1016/j.jphotobiol.2010.05.004 20638979 Wang, Y. Q., Zhang, H. M. & Tang, B. P. The interaction of C.I. Acid red 27 with human hemoglobin in solution. J. Photochem. Photobiol B 100 20638979 10.1016/j.jphotobiol.2010.05.004 65. Kritika N Comparative analysis of Cobalt ferrite and iron oxide nanoparticles using bimodal hyperthermia, along with physical and in Silico interaction with human hemoglobin J. Mater. Chem. B 2023 11 4785 4798 10.1039/d2tb02447k 37190982 Kritika, N. et al. Comparative analysis of Cobalt ferrite and iron oxide nanoparticles using bimodal hyperthermia, along with physical and in Silico interaction with human hemoglobin. J. Mater. Chem. B 11 37190982 10.1039/d2tb02447k 66. Hazra S Suresh Kumar G Structural and thermodynamic studies on the interaction of Iminium and alkanolamine forms of sanguinarine with hemoglobin J. Phys. Chem. B 2014 118 3771 3784 10.1021/jp409764z 24635139 Hazra, S. & Suresh Kumar, G. Structural and thermodynamic studies on the interaction of Iminium and alkanolamine forms of sanguinarine with hemoglobin. J. Phys. Chem. B 118 24635139 10.1021/jp409764z 67. Alpert, B., Jameson, D. M. & E R E R, G. W. TRYPTOPHAN EMISSION FROM HUMAN HEMOGLOBIN AND ITS ISOLATED SUBUNITS, n.d. 10.1111/j.1751-1097.1980.tb03674.x 7367467 68. Wang Q Binding interaction of Atorvastatin with bovine serum albumin: spectroscopic methods and molecular Docking Spectrochim Acta Mol. Biomol. Spectrosc. 2016 156 155 163 10.1016/j.saa.2015.12.003 26688207 Wang, Q. et al. Binding interaction of Atorvastatin with bovine serum albumin: spectroscopic methods and molecular Docking. Spectrochim Acta Mol. Biomol. Spectrosc. 156 10.1016/j.saa.2015.12.003 26688207 69. Zhang YF Zhou KL Lou YY Pan DQ Shi JH Investigation of the binding interaction between Estazolam and bovine serum albumin: Multi-spectroscopic methods and molecular Docking technique J. Biomol. Struct. Dyn. 2017 35 3605 3614 10.1080/07391102.2016.1264889 27882826 Zhang, Y. F., Zhou, K. L., Lou, Y. Y., Pan, D. Q. & Shi, J. H. Investigation of the binding interaction between Estazolam and bovine serum albumin: Multi-spectroscopic methods and molecular Docking technique. J. Biomol. Struct. Dyn. 35 27882826 10.1080/07391102.2016.1264889 70. K.A. Bostian’, Instrumentation for Differential Fluorescence Spectroscopy, (1977). 10.1016/0003-2697(77)90172-5 907139 71. Lakowicz JR Weber G Quenching of Fluorescence by Oxygen. A Probe for Structural Fluctuations in Macromoleculest 1966 UTC 10.1021/bi00745a020 PMC6959846 4795686 Lakowicz, J. R. & Weber, G. Quenching of Fluorescence by Oxygen. A Probe for Structural Fluctuations in Macromoleculest https://pubs.acs.org/sharingguidelines 10.1021/bi00745a020 PMC6959846 4795686 72. Manna A Chakravorti S Role of block copolymer-micelle nanocomposites in dye-bovine serum albumin binding: A combined experimental and molecular Docking study Mol. Biosyst 2013 9 246 257 10.1039/c2mb25368b 23175177 Manna, A. & Chakravorti, S. Role of block copolymer-micelle nanocomposites in dye-bovine serum albumin binding: A combined experimental and molecular Docking study. Mol. Biosyst 9 23175177 10.1039/c2mb25368b 73. Tong JQ Probing the adverse temperature dependence in the static fluorescence quenching of BSA induced by a novel anticancer hydrazone Photochemical Photobiological Sci. 2012 11 1868 1879 10.1039/c2pp25162k 22911144 Tong, J. Q. et al. Probing the adverse temperature dependence in the static fluorescence quenching of BSA induced by a novel anticancer hydrazone. Photochemical Photobiological Sci. 11 10.1039/c2pp25162k 22911144 74. Tian FF The adsorption of an anticancer hydrazone by protein: an unusual static quenching mechanism RSC Adv. 2012 2 501 513 10.1039/c1ra00521a Tian, F. F. et al. The adsorption of an anticancer hydrazone by protein: an unusual static quenching mechanism. RSC Adv. 2 75. Ross P. D. & Subramanian S. Thermodynamics of protein association reactions: forces contributing to Stability. Biochemistry 20 https://pubs.acs.org/sharingguidelines 10.1021/bi00514a017 7248271 76. Greenfield NJ Using circular dichroism spectra to estimate protein secondary structure Nat. Protoc. 2007 1 2876 2890 10.1038/nprot.2006.202 PMC2728378 17406547 Greenfield, N. J. Using circular dichroism spectra to estimate protein secondary structure. Nat. Protoc. 1 10.1038/nprot.2006.202 PMC2728378 17406547 77. Corchnoy SB Intramolecular proton transfers and structural changes during the photocycle of the LOV2 domain of phototropin 1 J. Biol. Chem. 2003 278 724 731 10.1074/jbc.M209119200 12411437 Corchnoy, S. B. et al. Intramolecular proton transfers and structural changes during the photocycle of the LOV2 domain of phototropin 1. J. Biol. Chem. 278 12411437 10.1074/jbc.M209119200 78. Micsonai A BeStSel: A web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra Nucleic Acids Res. 2018 46 W315 W322 10.1093/nar/gky497 29893907 PMC6031044 Micsonai, A. et al. BeStSel: A web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra. Nucleic Acids Res. 46 29893907 10.1093/nar/gky497 PMC6031044 ",
  "metadata": {
    "Title of this paper": "BeStSel: A web server for accurate protein secondary structure prediction and fold recognition from the circular dichroism spectra",
    "Journal it was published in:": "Scientific Reports",
    "URL": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12484645/"
  }
}